Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)

~ FDA removes clinical hold for pivotal Phase 2 MB-107 clinical trial ~ Company plans to enroll first patient in MB-107 pivotal trial in the second quarter of 2021 ~ Clinical outcomes in investigator-IND XSCID trials continue to show compelling efficacy

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

LEAVE A REPLY

Please enter your comment!
Please enter your name here